John H. Kihm v. David M. Mott

• Court: Court of Chancery of Delaware
• Decided: August 31, 2021
• Docket: C.A. No. 2020-0938-MTZ
• Status: Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

JOHN H. KIHM, individually and on ) behalf of all others similarly situated, ) ) Plaintiff, ) ) v. ) C.A. No. 2020-0938-MTZ ) DAVID M. MOTT, LEON O. ) MOULDER, DR. MARY LYNNE ) HEDLEY, TIMOTHY R. PEARSON, ) KAVITA PATEL, LAWRENCE M. ) ALLEVA, GARRY A. NICHOLSON, ) PASCALE WITZ, DR. BETH ) SEIDENBERG, NEW ENTERPRISE ) ASSOCIATES 13, L.P., NEA ) PARTNERS 13, L.P., NEA 13 GP, LTD, ) NEA 15 OPPORTUNITY FUND, L.P., ) NEA PARTNERS 15-OF, L.P., NEA 15 ) GP, LLC, NEW ENTERPRISE ) ASSOCIATES, INC., NEA ) MANAGEMENT COMPANY, LLC, ) CITIGROUP, INC., and CITIGROUP ) GLOBAL MARKETS, INC., ) ) Defendants. )

MEMORANDUM OPINION Date Submitted: May 11, 2021 Date Decided: August 31, 2021

Joel Friedlander and Jeffery M. Gorris, FRIEDLANDER & GORRIS, P.A., Wilmington, Delaware; R. Bruce McNew, COOCH & TAYLOR, P.A., Wilmington, Delaware; Randall J. Baron and David Wissbroecker, ROBBINS GELLER RUDMAN & DOWD LLP, San Diego, California; Christopher H. Lyons, ROBBINS GELLER RUDMAN & DOWD LLP, Nashville, Tennessee; Peretz Bronstein, BRONSTEIN, GEWIRTZ & GROSSMAN, LLC, New York, New York, Attorneys for Plaintiff. A. Thompson Bayliss and April M. Kirby, ABRAMS & BAYLISS LLP, Wilmington, Delaware; Peter L. Welsh and Elena Weissman Davis, ROPES & GRAY LLP, Boston, Massachusetts; Timothy R. Farrell, ROPES & GRAY LLP, Chicago, Illinois; Christian Reigstad, ROPES & GRAY LLP, New York, New York, Attorneys for Defendants David M. Mott, Leon O. Moulder, Dr. Mary Lynne Hedley, Timothy R. Pearson, Kavita Patel, Lawrence M. Alleva, Garry A. Nicholson, Pascale Witz, and Dr. Beth Seidenberg.

Paul D. Brown and Joseph B. Cicero, CHIPMAN BROWN CICERO & COLE, LLP, Wilmington, Delaware; Roger A. Lane and Courtney Worcester, HOLLAND & KNIGHT LLP, Boston, Massachusetts, Attorneys for Defendants New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, NEA 15 Opportunity Fund, L.P., NEA Partners 15-OF, L.P., NEA 15 GP, LLC, New Enterprise Associates, Inc., NEA Management Company, LLC.

Daniel A. Mason, PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP, Wilmington, Delaware; Bruce Birenboim, Susanna M. Buergel, and Christopher L. Filburn, PAUL, WEISS, RIFKIND, WHARTON & GARRISON, LLP, New York, New York, Attorneys for Defendants Citigroup, Inc. and Citigroup Global Markets, Inc.

ZURN, Vice Chancellor. In December 2018, the board of a public oncology company agreed to sell the

company to a major multinational pharmaceutical conglomerate in a cash tender

offer with a second-step merger. With the benefit of books and records obtained in

an action brought under 8 Del. C. § 220, a former stockholder in the target company

brought this post-closing class action complaint for damages, alleging the

acquisition was the product of actionable breaches of fiduciary duty by the

company’s directors. The plaintiff challenges the sale process as rushed and

inadequate; he also challenges the sale’s timing.

According to the plaintiff, the company’s long-time private equity sponsor

favored a near-term sale so that it could exit its position, cash out its investors, and

facilitate raising an important upcoming fund. In the complaint, the private equity

sponsor is everywhere and nowhere: the plaintiff offers pages of allegations about

the sponsor’s motivations, but does not assert the sponsor was a controlling

stockholder, nor that the sponsor or any of its agents had any specific role in the

flawed sale process. Instead, the plaintiff pins those flaws on the target’s financial

advisors and its managers.

The target’s board ultimately recommended its stockholders tender their

shares at the agreed-upon price of $75 per share, representing a 182% premium over

the stock’s unaffected trading price. In support of its recommendation, the board

issued an eighty-page disclosure statement discussing the proposal, including

1 fairness opinions from two financial advisors. An overwhelming majority of the

company’s stockholders chose to tender their shares; the acquisition closed in

January 2019.

On this motion to dismiss, the defendants—members of the target’s board, its

financial advisor, and the private equity sponsor—seek to “cleanse” the transaction

under Corwin v. KKR Financial Holdings LLC.1 This Court has observed the rhythm

of post-closing shareholder litigation: defendants hope to secure judicial deference

by pointing to a majority stockholder vote, then plaintiffs seek more rigorous review

by arguing a controlling stockholder or an uninformed vote places the transaction

beyond Corwin’s reach.2 But the plaintiff stops short of alleging the target’s private

equity sponsor was a controlling stockholder. Having declined to argue the tender

offer was coercive, the plaintiff is left with a single path to avoid Corwin: alleging

the target’s disclosures were inadequate and the stockholders uninformed. He points

to four omissions from the company’s recommendation statement, which he argues

make the disclosures deficient. After careful consideration, I conclude that none of

those claims are meritorious. Because I am satisfied that a fully-informed,

1 125 A.3d 304 (Del. 2015), aff’g In re KKR Fin. Hldgs. LLC S’holder Litig., 101 A.3d 980 (Del. Ch. 2014). 2 In re GGP, Inc. S’holder Litig., 2021 WL 2102326, at *1–2 (Del. Ch. May 25, 2021).

2 uncoerced majority of the target’s shareholders ratified the transaction, I grant the

pending motions to dismiss in full.

I. BACKGROUND3

Plaintiff John Kihm (“Plaintiff”) is a former stockholder of Tesaro Inc.

(“Tesaro” or the “Company”). Plaintiff’s Verified Class Action Complaint (the

“Complaint”) alleges breaches of fiduciary duty in connection with the January 2019

cash sale of Tesaro to GlaxoSmithKline, plc (“GSK”) for $75 per share, or

approximately $5.1 billion (the “Acquisition”).

A. Tesaro Raises Financing, Goes Public, Develops Its Flagship Product, And Considers A Sale.

Tesaro is an oncology-focused biopharmaceutical company. It was founded

in March 2010 by defendants Leon Moulder and Dr. Mary Lynne Hedley. Tesaro’s

initial financing primarily came from a private equity company called New

Enterprise Associates, Inc. (“NEA Parent”). NEA Parent invests through its

3 On this motion to dismiss, I draw the following facts from plaintiff’s Verified Class Action Complaint, available at Docket Item (“D.I.”) 1 [hereinafter “Compl.”], as well as the documents attached and integral to it. See, e.g., Himawan v. Cephalon, Inc., 2018 WL 6822708, at *2 (Del. Ch. Dec. 28, 2018); In re Gardner Denver, Inc. S’holders Litig., 2014 WL 715705, at *2 (Del. Ch. Feb. 21, 2014). Citations in the form of “Mason Decl. ––” refer to the exhibits attached to the Transmittal Declaration Pursuant to 10 Del. C. § 3927 of Daniel A. Mason in Support of Opening Brief of Citigroup Inc. and Citigroup Global Markets Inc. in Support of Their Motion to Dismiss the Verified Class Action Complaint, available at D.I. 26. Citations in the form of “Kirby Decl. ––” refer to the exhibits attached to the Declaration of April M. Kirby, Esq. in Support of the Opening Brief in Support of Director and Officer Defendants’ Motion to Dismiss, available at D.I. 30.

3 affiliated funds, including New Enterprise Associates 13, L.P.; NEA Partners 13,

L.P.; NEA 13 GP, LTD (together, “NEA 13”); NEA 15 Opportunity Fund, L.P.;

NEA Partners 15-OF, L.P.; and NEA 15 GP, LLC (together, “NEA 15,” and with

NEA 13 and NEA Parent, “NEA”).4 NEA continued to invest in Tesaro, and has

been the Company’s dominant venture capital investor. Through cumulative

investments of at least $58 million, NEA held 50.3% of Tesaro’s common stock by

May 2012.

In June 2012, Tesaro went public via an initial public offering (the “IPO”).

After the IPO, NEA held 43.1% of Tesaro’s common stock; NEA’s stake declined

to 35.3% in 2013, 27.4% in 2014, 24.6% in 2015, 23% in 2016, and 19% in 2017

after a series of secondary offerings and private placements. NEA maintained its

19% stake until the Acquisition, the largest stake among Tesaro’s private equity

backers.

During the relevant time period, Tesaro’s primary product was Zejula, the

brand name for Niraparib, a medicine that interferes with the growth and spread of

cancer cells by operating as a “PARP inhibitor.”5 In March 2017, the FDA approved

4 At the time of the Acquisition, NEA 13 owned 9,681,039 shares of Tesaro stock, through New Enterprise Associates 13, L.P. NEA 15 owned 739,516 shares, through NEA 15 Opportunity Fund, L.P. NEA Management Company, LLC, the ultimate parent of the entities in the NEA organization, is also a Defendant. 5 According to the Complaint, a “PARP inhibitor [is] a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase. PARP inhibitors inhibit DNA repair in cancer cells that are damaged through radiation therapy.” Compl. ¶ 114.

4 Niraparib for treatment of epithelial ovarian, fallopian tube, and primary peritoneal

cancer. Zejula became the leading PARP inhibitor in ovarian cancer treatment. It

also had the potential to expand to other uses. According to the Complaint, PARP

inhibitors may also be effective in treating other types of cancer and other life-

threatening diseases. Tesaro marketed Zejula in the United States and in several

European Union countries, and planned to expand into Israel and Canada.

Tesaro’s board of directors (the “Board”) began exploring outside financing

in early 2017. The Board retained Defendant Citigroup Inc. (together with its

affiliate, Defendant Citigroup Global Markets, Inc., “Citi”) to advise on a potential

sale; Christopher Hite was among the Citi bankers involved. Citi regularly provided

investment banking services to Tesaro. Citi’s non-public solicitation process lasted

from March to June 2017.6 Though Citi had discussions with four potential

acquirers, the process concluded without securing a sale.7 GSK was not among the

companies contacted as part of that process, as it was not then seen as a likely

acquirer.8

6 Kirby Decl. Ex. P at 16–17; see also Compl. ¶ 77. 7 Kirby Decl. Ex. P at 16–17; see also Compl. ¶ 77. 8 Kirby Decl. Ex. P at 17.

5 B. Tesaro’s Stock Price Drops, Causing Problems For NEA.

Tesaro’s stock price fluctuated throughout 2017 and into 2018. It hit its all-

time high, over $190 per share, on February 1, 2017. After the sale conversations

fell through, the stock price steadily declined. It fell to $120 per share in September

2017 and dropped to $70 per share in early 2018. By August 2018, when the Board

was once again considering financing options, the price had dropped to $30 per

share. It remained around that level until the Acquisition was announced, when it

spiked.

Tesaro’s plummeting stock price was bad for all investors, but allegedly hit

NEA particularly hard. In 2018, NEA was working on raising its next and biggest

fund, “NEA 17.” NEA invested in Tesaro primarily through NEA 13, which was of

the 2009 vintage. NEA 13’s performance was particularly important in 2018. The

Complaint explains the process of evaluating funds, including why NEA 13 was

critical to NEA’s 2018 fundraising efforts, in extensive detail.9 For now, it is enough

to say that NEA 13 would be closely scrutinized by potential NEA 17 investors, and

would therefore affect the volume of investment—and the fee NEA could charge.

Though some commentators considered NEA a second-tier venture capital firm, it

charged its investors a “super premium” 30% “carry” fee, typically only available to

9 See, e.g., Compl. ¶¶ 81–113.

6 the very best firms.10 To justify that exceptional fee for NEA 17, NEA 13 needed

exceptional returns, including from Tesaro.

At the end of 2017, NEA 13’s performance as compared to other funds of its

vintage was “solidly above median . . . but not quite upper quartile.”11 These above-

average, if unspectacular, returns were aided in part by Tesaro’s strong performance.

When Tesaro’s stock price plummeted in 2018, so did NEA 13’s performance; by

fall 2018, NEA 13’s returns were on track to drop below the median by the end of

the year. Without a change in fortunes, “NEA would have no realistic chance to

charge super-premium carry” on its NEA 17 fund, which was set to begin

fundraising in early 2019.12 According to Plaintiff, this created a strong incentive

for NEA to liquidate its investment in Tesaro.

C. Tesaro’s Board Considers Financing And A Sale.

Despite the company’s declining stock price, Tesaro’s internal projections

were bullish on Zejula and Tesaro’s ability to expand into other cancer drugs. Tesaro

used two sets of internal operating plans to guide operations: its short-term operating

plan, known as the Annual Operating Plan (“AOP”), updated once a year; and its

long-term strategic plan, known as the Long Range Plan (“LRP”), updated

10 Id. ¶ 90. 11 Id. ¶ 97. 12 Id. ¶ 105.

7 constantly on a more ad hoc basis. In February 2018, the Board approved Tesaro’s

2018 AOP. It then reviewed an updated LRP in August 2018. The LRP focused on

expanding Tesaro’s business into lung, gynecological, and breast cancers, and

predicted that the company could launch up to thirteen new drugs by 2023. Based

on these advances, the LRP projected 2025 “Global Base Case Revenues” between

$2 billion and nearly $5 billion on a risk-adjusted basis. A revised November 2018

LRP projected between $4.578 and $4.615 billion in risk-adjusted revenues by 2028

(the “November LRP”).13

These lofty goals depended on Zejula’s continued development and expansion

into new patient bases. Pending clinical trials to broaden Zejula’s uses looked

promising. If they proved successful, as the Board predicted, Zejula’s market would

dramatically expand. To fund the Company’s expansion, the LRP called for

additional financing. While Tesaro’s projected funding needs varied, the highest

estimates (based on the “all in” LRP) showed the company would need $285 million

of new money in 2019, and $225 million in 2020. These estimates were presented

to the Board in August 2018.

The Tesaro Board considered several fundraising options throughout 2018. In

March 2018, the Board began exploring potential co-development and co-promote

13 The November LRP projections eventually became part of an updated AOP, presumably for use in 2019.

8 collaborations on Zejula. These discussions initially spurred three proposals: a joint

venture to develop one of Tesaro’s proprietary molecules in China (“Chinese

NewCo”), a Zejula collaboration with Bristol Myers Squibb (“BMS” and the “BMS

Collaboration”), and a royalty deal on Zejula with Royalty Pharma (the “RP

Royalty”). The Board would ultimately elect to pursue the Acquisition.

1. Tesaro’s Board And Officers

At the time it considered these options, Tesaro’s Board was allegedly

intertwined with other NEA portfolio companies and NEA itself, although Plaintiff

stops short of asserting NEA was a controlling stockholder. Eight of Tesaro’s ten

directors at the time of the Acquisition are defendants in this action.

Tesaro’s founders, Moulder and Hedley, sat on the company’s pre-

Acquisition Board. The two founders also had key executive roles: Moulder was

Tesaro’s CEO, and Hedley was its president and COO. Through the Acquisition,

the founders received substantial compensation—well over $100 million each—for

their Tesaro shares, options, and restricted stock units.14 Both also received multi-

million dollar “golden parachute” compensation packages.15 After the Acquisition,

Hedley stayed in her role as president and COO of Tesaro, and Moulder became an

14 See Compl. ¶¶ 13 (alleging Moulder received $155,854,551), 19 (alleging Hedley received $112,500,429). 15 See id. ¶¶ 13 (alleging Moulder received ($10,997,196), 19 (alleging Hedley received $8,770,318).

9 NEA venture advisor. Both founders have served and continue to serve on the

boards of other NEA-backed biopharmaceutical companies.

Defendant David Mott became the Board’s chairperson in July 2011, shortly

after the Company was founded. He remained in that role until the Acquisition.

Throughout this period, Mott was a general partner at NEA, and led NEA’s $1 billion

health care investment practice. The Complaint emphasizes Mott’s role at NEA to

support Plaintiff’s that NEA’s divergent interests drove the Acquisition.16

Several other Tesaro Board members also have ties to NEA. Defendant Dr.

Kavita Patel, who joined the Board in 2016, has been a venture partner at NEA since

2017 and also serves on the boards of two NEA-backed companies.17 Tesaro

directors Lawrence M. Alleva, Garry A. Nicholson, and Pascale Witz also sat on

boards of other NEA portfolio companies. Patel, Alleva, Nicholson, and Witz each

received over $1 million for their Tesaro shares and options in connection with the

Acquisition. The final Board member Defendant is Dr. Beth Seidenberg, who was

also a partner at another private equity investor in Tesaro, nonparty Kleiner Perkins

16 E.g., id. ¶¶ 69–70 (alleging that “Mott’s conduct served to benefit each of the NEA Defendants” and attributing Mott’s conduct and knowledge to “all of the NEA Defendants”). While the Complaint alleges that Mott and NEA cashed out for a combined $782 million, plus $1.7 million for stock options, it appears that the vast majority of this payment went to NEA and not Mott individually. See Kirby Decl. Ex. P at 6. 17 The Complaint alleges that Patel’s relationship with NEA was not disclosed, but do not argue that this omission was material.

10 Caufield & Byers (“Kleiner Perkins”). Seidenberg has served on other boards with

Mott, and Kleiner Perkins has “deep co-investment relationships” with NEA.18

In addition to the Board members, the Complaint also names Timothy R.

Pearson, Tesaro’s CFO, as a defendant. Pearson was Mott’s colleague at

MedImmune, Inc., a company Mott founded in 1988. Allegedly as a result of his

relationship with Mott, Pearson had lucrative board seats at two other NEA-backed

biopharmaceutical companies. Pearson owned Tesaro stock and received over $11

million in cash compensation, plus over $4 million as a golden parachute, in

connection with the Acquisition.

This opinion refers to Moulder, Hedley, Mott, Patel, Alleva, Nicholson, Witz,

Seidenberg, and Pearson as the “Individual Defendants.”

2. Alternatives To The Acquisition

The Chinese NewCo transaction was presented to the Board in May 2018.

The proposal contemplated that the new company would market TSR-042, one of

Tesaro’s many proprietary molecules, for multiple uses in China. The Chinese

NewCo transaction would provide Tesaro with $80 million of expense relief and

represented $228 million in value to Tesaro through 2021. The new company was

projected to go public in two to three years, with Tesaro owning approximately 25%

of that entity. On October 20, the Board authorized management to enter into the

18 Compl. ¶ 57.

11 Chinese NewCo transaction in its discretion. Board discussion on the transaction

continued through at least November 8.

The other two proposals were substantially larger in scope, and would have

solved Tesaro’s projected cash crunch for at least 2019 and 2020. The BMS

Collaboration proposed to market all uses of Zejula, except the treatment of prostate

cancer, in all nations except Japan, South Korea, Taiwan, Russia, Australia, and

China. Tesaro would receive upfront consideration of $700 million, as well as up to

$640 million at developmental milestones, and up to $1 billion at commercial

milestones. It would have also obtained a license to several of BMS’s related

patents. Finally, the RP Royalty proposal would have provided $800 million in

upfront financing and royalties on worldwide future revenues of Zejula and three of

Tesaro’s proprietary molecules.

On August 17, the Board’s financing committee met and considered the

proposals. It concluded that the RP Royalty transaction was “the most viable and

attractive” alternative to bridge any cash gap.19 But as the Complaint explains, both

transactions would have created hurdles to a potential sale of the company. The

BMS Collaboration would have ceded partial control of Tesaro’s future to a

proposed Joint Development Committee, which would have made a change-in-

19 Id. ¶ 148.

12 control transaction for Tesaro “virtually impossible.”20 The RP Royalty deal

included a change-of-control penalty between $1.4 billion and $2.4 billion. Despite

these drawbacks, discussions on the BMS Collaboration continued through

November 5, and discussions on the RP Royalty transaction continued through

November 19. In the fall of 2018, Tesaro management publicly maintained that the

Company intended to obtain financing through partnerships, not the public capital

markets.

3. The Acquisition

The Complaint alleges NEA and Mott favored selling Tesaro over obtaining

more financing, in order to boost NEA 13’s performance and support NEA 17

fundraising efforts and fees. Plaintiff broadly contends NEA favored and

“engineered” the Acquisition by the end of 2018, without specifically identifying

any particular action.21

Plaintiff alleges the Acquisition conversations began not with the Board, but

with management and Citi. Citi was both Tesaro’s banker and GSK’s principal

relationship banker. Specifically, Hite also worked on a multi-billion-dollar joint

venture between GSK and Pfizer (the “GSK/Pfizer JV”), which was being negotiated

20 Id. ¶ 150. 21 See Compl. ¶ 230. As discussed infra, this allegation is unsupported and conclusory.

13 around the same time as the Acquisition. Hite was no longer involved with the

GSK/Pfizer JV by the time GSK made its first offer.22

Around June 2018, Hedley reached out to GSK’s Chief Scientific Officer and

R&D president to discuss a co-development or co-promote on Zejula. The

Complaint alleges such a collaboration would have been unlikely, given that GSK

did not have an oncology platform. Plaintiff alleges, on information and belief, that

these discussions were solely to transfer confidential due diligence about Tesaro to

make it a more appealing acquisition target.

Around the same time, Hite mentioned Tesaro to GSK as a potential

component of a broader acquisition strategy. Citi had routine strategic discussions

with GSK. Citi identified and screened “all biotech companies that had greater than

$500 million in revenue in 2024, focused on oncology, [whose] products were not

substantially partnered,” based on publicly available information.23 In one such

strategic discussion in June 2018, before the Tesaro Board had considered any

acquisition by GSK, Hite presented GSK with public marketing valuation materials

on Tesaro that he had prepared with Tesaro management.24 Citi presented several

analyses of acquiring multiple smaller companies in a “string of pearls” scenario,

22 Kirby Decl. Ex. M at 6. 23 Kirby Decl. Ex. M at 5; see Compl. ¶ 158. 24 Kirby Decl. Ex. M at 5–6; see Compl. ¶ 158.

14 and included Tesaro as a “pearl” in one of the analyses.25 These materials did not

suggest any particular transaction or a standalone purchase of Tesaro.26

Throughout that summer, Tesaro negotiated with GSK and others about a

potential collaboration on Zejula.27 On September 24, Hite met with GSK’s CFO

Scott Dingemans to discuss GSK making an offer to buy Tesaro.

At a September 27 meeting of the Board’s financing committee, Hite and Citi

presented Tesaro’s financing alternatives and advised that the RP Royalty

transaction resulted in the best value to shareholders, “assuming [Tesaro] remains

independent.”28 Hite did not mention a potential GSK acquisition at the September

27 financing committee meeting, but the next day, he informed the Board of his

discussions with Dingemans and GSK’s desire to discuss an acquisition proposal.

At that September 28 meeting, the Board “authorized management to . . . inform

[GSK] that the Company would consider an acquisition proposal for the entire

company from it.”29 Throughout October, the Board continued to consider financing

25 Kirby Decl. Ex. M at 5–6; see Compl. ¶ 158. 26 Kirby Decl. Ex. M at 6; see Compl. ¶ 158. 27 Though Plaintiff characterizes the co-development or co-promote discussions between Tesaro and GSK as a screen for transferring due diligence in furtherance of an acquisition, see Compl. ¶ 161, Plaintiff also alleges that no offer was made at this time because “discussions between Tesaro and GSK had focused exclusively on a potential co- development/co-promote collaboration respecting Zejula.” Id. ¶ 160. 28 Id. ¶ 162. 29 Id. ¶ 163.

15 alternatives. On October 20, it authorized management to enter into the Chinese

NewCo transaction.

On October 24, GSK made its initial proposal to acquire Tesaro for $66 in

cash per share. GSK indicated that it planned to keep Tesaro’s current management

and “organizational independence.”30 The Board rejected GSK’s offer on October

29 and continued negotiating with BMS. It retained Citi and Centerview Partners

LLC (“Centerview”) as financial advisors to advise on the sale process.31 Its

engagement letter with Citi provided for a $44 million total payment upon closing

the Acquisition, with no money owed if talks never reached the fairness opinion

stage. Without Board authorization, Citi reached out to seven potential strategic

buyers.

In November, the Board learned that Tesaro management was working on an

update to the LRP (the “November LRP”). Management also prepared alternative

forecasts, referred to respectively as “Case A” and “Case B.”32 At the November 8

Board meeting (the “November 8 Meeting”), Pearson explained these projections to

the Board and explained that Citi and Centerview would use Case A and Case B to

evaluate a potential acquisition. Case A was the “base case,” and Case B was the

30 Id. ¶ 165. 31 At various points, the Board also retained Hogan Lovells US LLP and Ropes & Gray LLP as legal advisors. Kirby Decl. Ex. P at 18, 21. 32 See id. at 24, 60; Compl. ¶ 191.

16 “low case.”33 The November LRP differed from Case A only in that it included two

projected revenue streams from Zejula—treating breast cancer and a certain type of

ovarian cancer known as “platinum resistant ovarian cancer” or “PROC”—that Case

A omitted. Overall, the November LRP projects roughly 7.05% higher revenue as

of 2028 than Case A.

Citi assumed that Case A would require $855 million in financing, and that

Case B would require $1.19 billion in financing. Based on these and other

assumptions, Citi and Centerview presented preliminary valuation analyses at the

November 8 Meeting for both Case A and Case B. Citi provided both discounted

cash flow (“DCF”) and sum-of-the-parts (“SOTP”) analyses, while Centerview

presented only one estimate for each case, apparently based on a DCF analysis.34

The following table summarizes those ranges on a per-share basis:35

Citi DCF Citi SOTP Centerview Case A $68.96 to $106.07 $79.60 to $95.95 $51.75 to $92.25 Case B $46.12 to $70.63 $52.15 to $64.10

33 Compl. ¶¶ 177–78. 34 Compl. ¶ 182. While the Complaint says Centerview presented “DCF/SOTP ranges,” Centerview’s fairness opinion appears to only employ a DCF analysis. Compare Compl. ¶ 182, with Kirby Decl. Ex. P at 44. 35 The Complaint does not break Citi’s SOTP analysis into Case A and Case B. See Compl. ¶ 182.

17 Citi and Centerview also presented per-share valuation ranges for the BMS

Collaboration and the RP Royalty proposals:36

Citi Centerview BMS Collaboration $51.52 to $83.58 $47.00 to $85.00 RP Royalty $58.11 to $87.39 N/A

Also at the November 8 Meeting, Citi presented materials regarding its conflict with

GSK. According to the minutes from that meeting, Hite reviewed Citi’s relationship

with GSK, including detail about its prior and current engagements and the fees

associated.37 A “[d]iscussion followed, during which [] Hite answered questions

from the Board.”38

On November 16, Bloomberg published an article reporting that Tesaro was

in acquisition discussions. Public speculation caused the stock price to rise by over

$20 per share.

On November 18, Citi reported that no buyer other than GSK had emerged.

It also delivered a revised bid from GSK for $69 per share, with a two-week

exclusive negotiating period. The Board proposed that it would agree to exclusivity

if GSK raised its bid by fifteen to twenty percent. On November 21, GSK raised its

36 These ranges include both Case A and Case B projections. Centerview’s valuation range for the RP Royalty transaction is not in the Complaint or in Plaintiff’s brief. See id. ¶ 183; D.I. 38 at 27. 37 Mason Decl. Ex. 8 at 5. But see Compl. ¶ 170 (“The minutes contain no detail of this discussion.”). 38 Mason Decl. Ex. 8 at 5.

18 offer to $75 per share in response, which Dingemans characterized as its “best and

final offer.”39 The Board met later that day with its financial and legal advisors.

After deliberating, the Board agreed to exclusivity and the parties began drafting a

merger agreement (the “Merger Agreement”).40

On November 29, Citi presented information about its conflicts of interest to

the Board (the “Conflict Presentation”).41 Notably, it discussed Hite’s June 2018

presentation to GSK.

39 Kirby Decl. Ex. P at 25; see also Compl. ¶ 173. 40 Kirby Decl. Ex. P at 25–26. 41 Kirby Decl. Ex. M. The Complaint alleges this meeting took place December 2. See Compl. ¶ 174. This is inconsistent with the Conflict Presentation itself, which is dated November 29. See Kirby Decl. Ex. M. Plaintiff appeared to back off this position in briefing. See D.I. 38 at 3. In either case, the Board saw the Conflict Presentation before it issued the Recommendation Statement.

19 Chris Hite is the senior Citi member of the [GSK] coverage team and as such regularly has strategic discuss[ions] with [GSK] concerning M&A and capital structure. In connection with such discussions, in June 2018, Chris Hite reviewed materials labeled “Preliminary draft subject to further discussion and revision” with GSK that included a screen of all biotech companies that had greater than $500 million in revenue in 2024, focused on oncology, and where their products were not substantially partnered. The preliminary draft materials also included a general overview of the biopharma landscape, including public information overviews of [Tesaro] and multiple other industry participants. The preliminary draft materials also had hypothetical acquisitions of two larger biotech companies compared to a hypothetical acquisition of three smaller companies that was termed a “string of pearls” scenario. In this hypothetical analysis, the three companies in the string of pearls analysis were aggregated together in order to compare to the larger acquisition scenarios. . . . In one version of the preliminary draft materials, [Tesaro] was included as one of the companies aggregated into the string of pearls. No individual hypothetical acquisition analysis of [Tesaro] alone was included in the preliminary draft materials. Any references to [Tesaro] were based solely on public information.42

Citi also disclosed to the Board its role in advising GSK on a “confidential, unrelated

non-pharmaceutical strategic transaction,” which was the GSK/Pfizer JV.43

42 Kirby Decl. Ex. M at 5–6. 43 Kirby Decl. Ex. M at 6.

20 On December 2, Citi and Centerview presented their opinions that the

Acquisition was fair to Tesaro stockholders from a financial point of view. 44 In

connection with their fairness opinions, Citi and Centerview provided final valuation

ranges. These were nearly identical to those presented at the November 8 Meeting,

with Citi’s adjusted slightly up and Centerview’s adjusted slightly down:45

Citi DCF Citi SOTP Centerview DCF Case A $69.52 to $107.00 $79.45 to $95.85 $52.25 to $93.00 Case B $46.38 to $71.14 $51.95 to $63.95

After considering recommendations from Citi, Centerview, and legal advisors, the

Board unanimously voted to approve the Acquisition at $75 per share. This

represented a 182% premium to the stock’s price on November 15, the last full

trading day before Bloomberg reported Tesaro was considering a merger.

On the morning of December 3, GSK’s board met to review the Acquisition,

and authorized GSK to enter into the Merger Agreement governing a tender offer

followed by a second-step merger under 8 Del. C. § 251(h).46 The parties executed

the Merger Agreement and publicly announced the Acquisition that morning before

NASDAQ trading opened.47 The Acquisition was set to close in January 2019.

44 See Kirby Decl. Ex. P at 26; see also Compl. ¶ 174. 45 See Compl. ¶ 184; Kirby Decl. Ex. P at 35. 46 See Kirby Decl. Ex. P at 27. 47 See id.

21 On December 14, Tesaro filed its Schedule 14D-9, recommending that

stockholders tender their shares (the “Recommendation Statement”).48 The eighty-

page Recommendation Statement included eleven pages dedicated to the

background of the Acquisition and the negotiations leading up to it.49 It also

disclosed Citi’s and Centerview’s fairness opinions, potential conflicts of interests,

information about Case A and Case B, and the alternative financing transactions the

Board explored.

D. Plaintiff Seeks Books And Records.

On January 3, 2019, Plaintiff served the Board with a demand to inspect

Tesaro’s books and records pursuant to 8 Del. C. § 220. The purpose of the demand

was to investigate potential wrongdoing or mismanagement in connection with the

Acquisition, as well several disclosure concerns. The Board rejected Plaintiff’s

demand, and he filed a complaint in this Court on January 11 (the “Section 220

Action”).50 Aside from Tesaro’s answer, filed on February 4, the Section 220

Action’s docket sat idle until the Court requested a joint status report in August 2019.

The parties eventually agreed to a stipulated production, governed by a

48 See generally id. 49 See id. at 16–27. 50 The Section 220 Action is captioned Kihm v. Tesaro, Inc., C.A. No. 2019-0022-MTZ.

22 confidentiality agreement, and ultimately agreed to dismiss the case. Plaintiff did

not substantively challenge the Acquisition during that time.

E. Tesaro Stockholders Approve The Acquisition.

The tender offer expired on January 18, 2019. 50,118,797 shares were

tendered, representing approximately 82.8% of Tesaro’s outstanding shares.51 GSK

acquired the remaining shares through a merger pursuant to Section 251(h) on

January 22.

After the Acquisition was announced, NEA promptly began touting it in its

marketing materials for NEA 17. The NEA 17 pitchbook emphasized NEA’s

sustained “top tier returns” and boasted major distributions and a “liquidity

engine.”52 It specifically highlighted Tesaro as one of three examples of NEA’s

growth and success leading to “big outcomes and meaningful impact across

sectors.”53 NEA 17 ultimately met its goal to raise $3.6 billion at a 30% super-

premium carry. The Complaint alleges that NEA could not have made its claims, or

successfully raised NEA 17 with a super-premium carry, without the Acquisition.

51 Kirby Decl. Ex. R at 3. 52 Compl. ¶¶ 110, 112. 53 Id. ¶ 113.

23 F. Plaintiff Files This Action.

On November 2, 2020, Plaintiff filed his class action Complaint challenging

the Acquisition. The Complaint asserts four counts. Count I alleges breaches of

fiduciary duty against Moulder, Hedley, and Pearson in their capacities as officers.

Count II alleges breaches of fiduciary duty against Mott, Moulder, Patel, Alleva,

Hedley, Nicholson, Witz, and Seidenberg in their capacities as directors. Count III

alleges NEA aided and abetted the Individual Defendants’ breaches. Count IV

similarly alleges Citi aided and abetted the Individual Defendants’ breaches. On

January 20, 2021, Defendants filed three motions to dismiss the Complaint under

Court of Chancery Rule 12(b)(6) (the “Individual Defendants’ Motion,” the

“Citibank Motion,” and the “NEA Motion,” together, the “Motions”).54 The parties

fully briefed the Motions and the Court heard oral argument on May 11.55

II. ANALYSIS

The standards governing a motion to dismiss under Court of Chancery Rule

12(b)(6) for failure to state a claim for relief are well settled:

54 D.I. 24; D.I. 27; D.I. 30. 55 D.I. 65; D.I. 66 [hereinafter “Hr’g Tr.”].

24 (i) all well-pleaded factual allegations are accepted as true; (ii) even vague allegations are “well-pleaded” if they give the opposing party notice of the claim; (iii) the Court must draw all reasonable inferences in favor of the non-moving party; and ([iv]) dismissal is inappropriate unless the “plaintiff would not be entitled to recover under any reasonably conceivable set of circumstances susceptible to proof.”56

Thus, the touchstone “to survive a motion to dismiss is reasonable

‘conceivability.’”57 This standard is “minimal”58 and “plaintiff-friendly.”59 “Indeed,

it may, as a factual matter, ultimately prove impossible for the plaintiff to prove his

claims at a later stage of a proceeding, but that is not the test to survive a motion to

dismiss.”60 Despite this forgiving standard, the Court need not “accept conclusory

allegations unsupported by specific facts” or “draw unreasonable inferences in favor

of the non-moving party.”61 “Moreover, the court is not required to accept every

strained interpretation of the allegations proposed by the plaintiff.”62

56 Savor, Inc. v. FMR Corp., 812 A.2d 894, 896–97 (Del. 2002) (citations omitted); accord In re Baker Hughes Inc. Merger Litig., 2020 WL 6281427, at *5 (Del. Ch. Oct. 27, 2020). 57 Cent. Mortg. Co. v. Morgan Stanley Mortg. Cap. Hldgs. LLC, 27 A.3d 531, 537 (Del. 2011). 58 Id. at 536 (citing Savor, 812 A.2d at 896). 59 See, e.g., Clouser v. Doherty, 175 A.3d 86 (Del. 2017) (TABLE); In re Trados Inc. S’holder Litig. (Trados I), 2009 WL 2225958, at *9 (Del. Ch. July 24, 2009). 60 Cent. Mortg. Co., 27 A.3d at 536. 61 Price v. E.I. du Pont de Nemours & Co., 26 A.3d 162, 166 (Del. 2011) (citing Clinton v. Enter. Rent-A-Car Co., 977 A.2d 892, 895 (Del. 2009)), overruled on other grounds by Ramsey v. Ga. S. Univ. Advanced Dev. Ctr., 189 A.3d 1255, 1277 (Del. 2018). 62 Trados I, 2009 WL 2225958, at *4 (internal quotation marks omitted) (quoting In re Gen. Motors (Hughes) S’holder Litig., 897 A.2d 162, 168 (Del. 2006)).

25 The Individual Defendants argue that the fiduciary duty claims in Counts I

and II must be dismissed under Corwin63 because a fully informed, uncoerced

majority of Tesaro shareholders approved the Acquisition by tendering their shares,

and, therefore, the business judgment rule unrebuttably applies. Even if Corwin is

inapplicable, the Individual Defendants argue that Plaintiff’s fiduciary duty counts

fail on their merits. NEA and Citi argue that the aiding and abetting claims against

them in Counts III and IV must be dismissed for lack of a predicate breach and, in

the alternative, because Plaintiff failed to plead knowing participation in any such

breach.

A. Counts I and II: Breach of Fiduciary Duty

Counts I and II allege breaches of fiduciary duty against the Individual

Defendants. Because Tesaro stockholders received cash for their shares, the

Acquisition is presumptively subject to at least enhanced scrutiny under Revlon, Inc.

v. MacAndrews & Forbes Holdings, Inc.64 But the Acquisition was ratified when a

63 125 A.3d at 306. 64 506 A.2d 173 (Del. 1986); see Chester Cty. Empls.’ Ret. Fund v. KCG Hldgs., Inc., 2019 WL 2564093, at *10 (Del. Ch. June 21, 2019) (citing Revlon, 506 A.2d at 184); accord In re Mindbody, Inc., 2020 WL 5870084, at *13 (Del. Ch. Oct. 2, 2020) (“The cash-for-stock Merger was a final-stage transaction presumptively subject to enhanced scrutiny under Revlon.”). Plaintiff theorizes that the Acquisition is subject to entire fairness review because a majority of the Board was not disinterested and independent. D.I. 38 at 60–61. “[E]ven if plaintiffs had pled facts from which it was reasonably inferable that a majority of [Company] directors were not independent, the business judgment standard of review still would apply to the merger because it was approved by a majority of the shares held by disinterested stockholders of [Company] in a vote that was fully informed.” KKR, 101

26 fully-informed majority of Tesaro stockholders tendered their shares, in the absence

of a conflicted controlling stockholder. Thus, under Corwin, the business judgment

is the appropriate standard of review.65 Because Plaintiff does not allege waste, his

breach of fiduciary duty claims against the Individual Defendants must be dismissed.

Corwin gives rise to the irrebuttable presumption of the business judgment

rule when a transaction “is approved by a fully informed, uncoerced vote of the

disinterested stockholders.”66 As Vice Chancellor Glasscock recently explained:

[Corwin] stands for the proposition that where the stockholder-owners of a corporation are given an opportunity to approve a transaction, are fully informed of the facts material to the transaction, and where the transaction is not coercive, there is no agency problem for a court to review, and litigation challenging the transaction is subject to dismissal under the business judgment rule. 67

To obtain the protection of Corwin’s presumption, Defendants must “demonstrate

that the [cash-out Acquisition] has been approved by a fully informed, uncoerced

majority of the disinterested stockholders.”68 “Stockholder approval of a merger

A.3d at 1003; accord In re Merge Healthcare Inc., 2017 WL 395981, at *6 (Del. Ch. Jan. 30, 2017). 65 125 A.3d at 306. 66 Id. at 309. 67 In re USG Corp. S’holder Litig., 2020 WL 5126671, at *1 (Del. Ch. Aug. 31, 2020). 68 KCG, 2019 WL 2564093, at *10 (internal quotation marks omitted) (quoting Corwin, 125 A.3d at 306).

27 under Section 251(h) by accepting a tender offer has the same cleansing effect as a

vote in favor of that merger.”69

Here, Plaintiff does not allege that the tender offer on the Acquisition was

coerced or that the Acquisition failed to receive the approval of a disinterested

majority of stockholders. Nor does Plaintiff assert that NEA was a conflicted

controlling stockholder, which would preclude Corwin cleansing and subject the

Acquisition, and the Individual Defendants, to entire fairness review.70 Thus, the

inquiry is whether “Plaintiff has pled facts from which one might reasonably

conceive that the vote was not fully informed.”71 If Plaintiff makes such a showing,

69 English v. Narang, 2019 WL 1300855, at *6 (Del. Ch. Mar. 20, 2019) (alterations and internal quotation marks omitted) (quoting In re Volcano Corp. S’holder Litig., 143 A.3d 727, 738 (Del. Ch. 2016), aff’d, 156 A.3d 697 (Del. 2017) (TABLE)), aff’d, 222 A.3d 581 (Del. 2019) (TABLE). 70 As Vice Chancellor Laster has aptly explained: The Corwin decision states that the cleansing effect of a stockholder vote does not apply to a transaction subject to the entire fairness standard. But despite this phrasing, Corwin precludes cleansing only when entire fairness applies ab initio because of the presence of a conflicted controlling stockholder. Firefighters’ Pension Sys. of City of Kan. City, Mo. Tr. v. Presidio, Inc., 251 A.3d 212, 254 (Del. Ch. 2021) (citing Larkin v. Shah, 2016 WL 4485447, at *13 (Del. Ch. Aug. 25, 2016)). Plaintiff does not make such an argument and, in fact, has distanced himself from this position. See Hr’g Tr. 67:5–9 (“Defendants argue, again, this -- that, you know, for entire fairness we have to show that they dominated a control. That’s not our theory. We don’t -- we don’t say to any -- there was a controller.”); see also D.I. 38 at 60– 61 (arguing that “the sale is subject to entire fairness review” but not arguing that NEA was a controller). 71 In re Saba Software, Inc. S’holder Litig., 2017 WL 1201108, at *8 (Del. Ch. Mar. 31, 2017) (citing In re Solera Hldgs., Inc. S’holder Litig., 2017 WL 57839, at *7 (Del. Ch. Jan. 5, 2017)).

28 “Corwin will not apply, the business judgment rule will not be available to the

Individual Defendants at the pleadings stage and enhanced scrutiny will be the

standard of review.”72 If the stockholders were fully informed, the Motions must be

granted with respect to Counts I and II because Plaintiff does not allege waste.73

In evaluating whether stockholders were fully informed, the Court must

consider “whether the Company’s disclosures apprised stockholders of all material

information and did not materially mislead them.”74 “At the pleading stage, that

requires [the Court] to consider whether Plaintiff’s complaint, when fairly read,

supports a rational inference that material facts were not disclosed or that the

disclosed information was otherwise materially misleading.”75 While defendants

bear the ultimate burden of “demonstrating that the stockholders were fully informed

when relying on stockholder approval to cleanse a challenged transaction,”76 a

plaintiff challenging the transaction must “first identify a deficiency in the operative

disclosure document.”77 If the plaintiff makes such a showing, “the burden [falls] to

72 Id. 73 See id. (citing Singh v. Attenborough, 137 A.3d 151, 151–52 (Del. 2016), and then citing Volcano, 143 A.3d at 750). 74 Morrison v. Berry, 191 A.3d 268, 282 (Del. 2018) (citing Appel v. Berkman, 180 A.3d 1055, 1057 (Del. 2018)). 75 Id. (citing Berkman, 180 A.3d at 1064). 76 Volcano, 143 A.3d at 748. 77 Solera, 2017 WL 57839, at *8.

29 defendants to establish that the alleged deficiency fails as a matter of law in order to

secure the cleansing effect of the vote.”78 This inquiry is necessarily “fact-intensive,

and the Court should deny a motion to dismiss when developing the factual record

may be necessary to make a materiality determination as a matter of law.”79

The Delaware Supreme Court recently described the “materiality” standard in

Morrison v. Berry:

An omitted fact is material if there is a substantial likelihood that a reasonable shareholder would consider it important in deciding how to vote. Framed differently, an omitted fact is material if there is a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the total mix of information made available. But, to be sure, this materiality test does not require proof of a substantial likelihood that disclosure of the omitted fact would have caused the reasonable investor to change his vote.80

78 Id. 79 KCG, 2019 WL 2564093, at *10 (compiling sources). 80 191 A.3d at 282–83 (footnotes and internal quotation marks omitted) (quoting Rosenblatt v. Getty Oil Co., 493 A.2d 929, 944 (Del. 1985)); accord TSC Indus., Inc. v. Northway, Inc., 426 U.S. 438, 449 (1976) (“An omitted fact is material if there is a substantial likelihood that a reasonable shareholder would consider it important in deciding how to vote. . . . It does not require proof of a substantial likelihood that disclosure of the omitted fact would have caused the reasonable investor to change his vote. What the standard does contemplate is a showing of a substantial likelihood that, under all the circumstances, the omitted fact would have assumed actual significance in the deliberations of the reasonable shareholder. Put another way, there must be a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the ‘total mix’ of information made available.”).

30 “Just as disclosures cannot omit material information, disclosures cannot be

materially misleading.”81 The Morrison Court explained the standard for evaluating

whether partial disclosures are materially misleading:

As we said in Arnold v. Society for Savings Bancorp, Inc., “once defendants traveled down the road of partial disclosure of the history leading up to the Merger . . . they had an obligation to provide the stockholders with an accurate, full, and fair characterization of those historic events.” And, in Zirn v. VLI Corp., we explained that, “even a non-material fact can, in some instances, trigger an obligation to disclose additional, otherwise non-material facts in order to prevent the initial disclosure from materially misleading the stockholders.”82

To be sure, facts are not necessarily material simply because a stockholder may find

them “helpful.”83 Delaware courts are cautious in “balancing the benefits of

additional disclosures against the risk that insignificant information may dilute

potentially valuable information.”84

81 Id. at 283. 82 Id. (alterations in original) (footnotes removed) (quoting 650 A.2d 1270, 1280 (Del. 1994), and then quoting 681 A.2d 1050, 1056 (Del. 1996)). 83 Dent v. Ramtron Int’l Corp., 2014 WL 2931180, at *10 (Del. Ch. June 30, 2014) (“Delaware law does not require information to be disclosed simply because that information might be helpful.” (internal quotation marks omitted) (quoting Skeen v. Jo– Ann Stores, Inc., 750 A.2d 1170, 1174 (Del. 2000))). 84 Volcano, 143 A.3d at 749 (citing Solomon v. Armstrong, 747 A.2d 1098, 1128 (Del. Ch. 1999), aff’d, 746 A.2d 277 (Del. 2000) (TABLE)).

31 Counterbalancing the mandate for complete disclosure, of course, is recognition of the risk of inundating the stockholder with so much information that the proxy clouds, rather than clarifies, the stockholder’s decision. A complaint does not state a disclosure violation by noting picayune lacunae or “tell-me-more” details left out.85

“One sufficiently alleged disclosure deficiency will defeat a motion to dismiss

under Corwin.”86 Here, Plaintiff alleges four separate disclosure problems that, in

his view, preclude Corwin’s application to the Acquisition. I address each in turn.87

a. The November LRP Projections

Plaintiff’s primary argument is that the Recommendation Statement omitted

mention of projections from the November LRP and, instead, only disclosed that the

Board considered Case A and Case B. Defendants argue that the November LRP

projections included speculative projections regarding yet-undeveloped uses of

Zejula to treat breast cancer and PROC, making them unreliable. Alternatively,

Defendants argue that the minimal difference between the November LRP

projections and the Case A projections renders further disclosure unnecessary.

85 Salladay v. Lev, 2020 WL 954032, at *12 (Del. Ch. Feb. 27, 2020) (footnotes omitted) (compiling sources). 86 Mindbody, 2020 WL 5870084, at *26. 87 Defendants argue I should not consider Plaintiff’s alleged disclosure deficiencies given that he waited until after the Transaction closed to assert them. “Given that I find each of the disclosure challenges to lack any merit, I decline to reach the issue of whether Plaintiff[] should be barred by waiver, laches or otherwise from raising disclosure deficiencies here.” In re Rouse Props., Inc., 2018 WL 1226015, at *22 n. 186 (Del. Ch. Mar. 9, 2018).

32 The Recommendation Statement included two full-page spreadsheets of Case

A and Case B projections through the year 2030.88 The Recommendation Statement

discussed these projections; first, in the context of the November 8 Meeting.

On November 7 and 8, 2018, the Company Board convened a regularly- scheduled Company Board meeting. Various members of the Company’s management, along with representatives from Ropes & Gray, Hogan Lovells, Citi and Centerview attended the portion of the Company Board meeting at which the Company’s financial projections were presented and discussed. Mr. Pearson presented the two sets of financial projections: the Case A Forecasts and the Case B Forecasts (see “Certain Company Management Forecasts”). Representatives from Citi updated the Company Board on activities to determine potential interest in a strategic transaction involving the Company, and Citi and Centerview each discussed a preliminary financial analyses of the Company, based in part upon the Case A Forecasts and the Case B Forecasts. Following these presentations, the Company Board discussed and considered the Company’s capital requirements, potential business development and financing options, including the proposed synthetic royalty transaction with Party C, the Chinese Newco License, [GSK’s] October 24 acquisition proposal and a plan for continued engagement with [GSK].89

In the section titled “Certain Company Management Forecasts,” the

Recommendation Statement described the Case A and Case B projections:

88 Kirby Decl. Ex. P at 59–60. 89 Id. at 24.

33 In connection with its annual preparation of the Company’s long-range plan, the Company’s management prepared unaudited nonpublic prospective financial projections for the Company as a stand-alone company, without giving effect to the Merger, and adjusted for the probability of success of each Company product. These prospective financial projections were prepared and updated by the Company’s management, and reviewed and discussed with the Company Board, from the summer of 2018 to November 2018. The Company Board used these prospective financial projections to assist in its decision- making process in determining to accept [GSK’s] proposal to acquire the Company and were used by the Company’s financial advisors in their respective opinions . . . .

The Case A Forecasts were prepared by the Company’s management based on assumptions they believed to be optimistic, but achievable. The Case A Forecasts reflect numerous assumptions including, (i) the probability of success and regulatory approval, commercial launch success, market size, market share, competition, pricing, and reimbursement for each of the Company’s products, including [Zejula and several proprietary molecules], and other immuno-oncology assets, (ii) research and development expenses, sales, general and administrative expenses, and other operating expenses, and (iii) other relevant factors relating to the Company’s long-range strategic plan, as well as how certain of these assumptions and estimates may change over time. The foregoing is a summary of certain key assumptions and estimates and does not purport to be a comprehensive overview of all assumptions and estimates reflected in the projections prepared by Company management. . . .

34 The Case B Forecasts were prepared by the Company’s management based on more conservative assumptions. Key assumption differences between the two cases include, for Case B, (i) reduced market share for the Company’s products, including [Zejula and several proprietary molecules], and other immuno-oncology assets, (ii) lower PD-L1 testing rates and reduced time on therapy in certain indications for [Zejula], and (iii) lower operating expenses due to the lower revenue. For purposes of preparing the Case B Forecasts, the Company assumed that it would successfully implement a convertible note offering and several secondary equity offerings to raise aggregate net proceeds of approximately $1.19 billion over the next several years.90

The Recommendation Statement also included the bankers’ full fairness

opinions, which relied on and discussed Case A and Case B.91 The Recommendation

Statement did not disclose the figures projected in any iteration of the LRP, including

the November LRP.

While there “is no per se duty under Delaware law to disclose . . . financial

projections given to and relied upon by a financial advisor,”92 Delaware law

recognizes the value of projections to stockholders considering a cash-out

transaction. As then-Vice Chancellor Strine observed in In re PNB Holding Co.

Shareholders Litigation:

90 Id. at 58. 91 Id. at 30–47, 68–74. 92 See Dent, 2014 WL 2931180, at *11.

35 In the context of a cash-out merger, reliable management projections of the company’s future prospects are of obvious materiality to the electorate. After all, the key issue for the stockholders is whether accepting the merger price is a good deal in comparison with remaining a shareholder and receiving the future expected returns of the company.93

But even in a cash-out transaction, when stockholders are comparing cash on the

table to their stock’s potential upside, not every projection is material.94 “Delaware

law does not require disclosure of inherently unreliable or speculative information

which would tend to confuse stockholders or inundate them with an overload of

information.”95 Because projections are inherently uncertain, materiality requires

reliability: projections are typically material only if “the circumstances of their

preparation support the conclusion that they are reliable enough to aid the

93 In re PNB Hldg. Co. S’holders Litig., 2006 WL 2403999, at *15 (Del. Ch. Aug. 18, 2006). 94 See id. at *16 (“The projections at issue fall into the category of documents that courts have referred to as ‘soft information,’ and the standard by which to determine whether or not soft information, such as pro formas and projections, must be disclosed has troubled courts and commentators. Projections of future performance are the kind of soft information that necessarily bespeaks caution, but they are also useful, particularly in the context of a cash-out merger. Even in the cash-out merger context, though, it is not our law that every extant estimate of a company’s future results, however stale or however prepared, is material.”) (footnotes omitted) (citing Weinberger v. Rio Grande Indus., Inc., 519 A.2d 116, 127 (Del. Ch.1986)). 95 Arnold, 650 A.2d at 1280.

36 stockholders in making an informed judgment.”96 As a general rule, management

projections made in the ordinary course of business are reliable.97

Plaintiff argues that because the LRP projections were created in Tesaro’s

ordinary course of business, they are presumptively reliable and thus, their omission

was material. While reliability is a prerequisite to materiality, it does not equate to

materiality. Even reliable projections need not be disclosed if it is unlikely that doing

so would “significantly alter[] the total mix of information” available to

96 PNB, 2006 WL 2403999, at *16 (emphasizing that “[t]he word reliable is critical” to the materiality inquiry); see also KCG, 2019 WL 2564093, at *13 (“Thus, under PNB, if the circumstances surrounding the preparation of interim projections reveal them to be reliable enough to aid stockholders in making an informed judgment, they should be disclosed, regardless of whether they were the final projections relied upon by the Board. By logical extension, if the circumstances surrounding the preparation of final projections relied upon by the Board and disclosed to the stockholder cast doubt on their reliability, then those circumstances should be disclosed.” (footnotes omitted) (citing PNB, 2006 WL 2403999, at *16)). 97 E.g., Cede & Co. v. Technicolor, Inc., 2003 WL 23700218, at *7 (Del. Ch. July 9, 2004) (“When management projections are made in the ordinary course of business, they are generally deemed reliable.” (citing In re Radiology Assocs., Inc. Litig., 611 A.2d 485, 490– 91 (Del. Ch. 1991))), aff’d in part, rev’d in part, 884 A.2d 26 (Del. 2005).

37 stockholders.98 When the difference between disclosed and undisclosed projections

is insubstantial, this Court has declined to compel further disclosure.99

Even assuming the November LRP projections were reliable, I cannot

conclude that their omission was material because their inclusion would not have

significantly altered the total mix of information available to Tesaro stockholders.

The only difference between the November LRP projections and Case A is Case A’s

omission of two potential revenue streams (using Zejula to treat breast cancer and

PROC) included in the November LRP. Their elimination does not appear to have

created a material difference between the projections, at least in the short term. The

following chart comes from the “LRP Case Review” presented to the Board,

98 See Morrison, 191 A.3d at 283 (internal quotation marks omitted); David P. Simonetti Rollover IRA v. Margolis, 2008 WL 5048692, at *10 (Del. Ch. June 27, 2008); Wayne Cty. Empls.’ Ret. Sys. v. Corti, 954 A.2d 319, 333 (Del. Ch. 2008); see also In re Cogent, Inc. S’holder Litig., 7 A.3d 487, 511 (Del. Ch. 2010) (“Whether a particular piece of an investment bank’s analysis needs to be disclosed, however, depends on whether it is material, on the one hand, or immaterial minutia, on the other.”); Saba Software, 2017 WL 1201108, at *10 (same). 99 See Simonetti, 2008 WL 5048692, at *10 (“Although including the more optimistic projections in the Proxy Statement and then explaining why they were not relied upon may have been somewhat helpful to stockholders, it is doubtful that any such additional disclosures would have materially altered the total mix of information provided.”); Corti, 954 A.2d at 333 (“Plaintiff has not explained how receiving information in addition to the financial data already disclosed will significantly alter the total mix of information available, especially when plaintiff itself admits that the current projections are generally the same as those already disclosed.” (footnotes, alterations, and internal quotation marks omitted) (quoting In re CheckFree Corp. S’holders Litig., 2007 WL 3262188, at *2 (Del. Ch. Nov. 1, 2007))).

38 produced in the Section 220 Action, and referenced in the Complaint.100 It depicts

total annual revenue across the following projections, from highest to lowest: the

“2018 LRP,” the November LRP, Case A, and Case B. The middle two lines, both

in shades of light grey, depict Case A and the November LRP.101

The November LRP projections and the Case A projections are nearly identical

through at least 2023 or 2024. Their divergence is almost completely confined to

the second half of the ten-year projections, where the exact figures are inherently

more speculative. At the height of this gap, the November LRP predicts only a

7.05% increase in total 2028 revenue over the Case A projections.102 Disclosing the

100 See Kirby Decl. Ex. L at 4; Compl. ¶¶ 169, 177. 101 See Kirby Decl. Ex. L at 4. 102 See id. This gap is larger than the delta between the August LRP and Case A, which was closer to 5.83% in 2028. See id..

39 marginally higher projections in the November LRP would not have “significantly

altered the total mix of information” available to Tesaro stockholders. 103 For the

same reason, their omission was also not “materially misleading,” as Plaintiff

suggests.104

103 See Morrison, 191 A.3d at 283 (internal quotation marks omitted). A review of cases assessing the sufficiency of disclosed projections in light of higher, undisclosed projections reveals that a more substantial, more immediate difference is typically considered material, while smaller deltas are not. For example, in Simonetti, the Court concluded that disclosure of projections predicting 2.36% higher revenue in the year following the merger likely would not have significantly altered the total mix of information provided to stockholders. See 2008 WL 5048692, at *10 (“The Proxy Statement sets forth projections estimating full year 2008 revenues at $495.8 million; by way of comparison, [the undisclosed projection] estimates 2008 revenues at $507.5 million.”); see also Corti, 954 A.2d at 333 (holding that undisclosed projections that are “generally the same as those already disclosed” were not material). By contrast, the cases on which Plaintiff relies address meaningfully different projections. In City of Warren General Employees’ Retirement System v. Roche, for example, the Court found an omitted projection that included a substantial acquisition plan to be material. 2020 WL 7023896, at *21 (Del. Ch. Nov. 30, 2020). That plan “projected to add $98 million in yearly EBITDA” within three years of the challenged transaction, “representing approximately 25% of” the projected adjusted EBITDA for that year, as well as adding “$20 million in EBITDA,” for the first year of projections, an approximately 8% increase in that year alone. Id. The Court concluded that omitting the acquisition plan altered the total mix of information available to stockholders considering a recommended buyout. Id. The November LRP, which projected nearly identical revenue for five years before showing a slight deviation ten years out, looks more like the immaterial omission in Simonetti than the material omission in Roche. I do not mean to suggest any bright line rule keying alterations to the total mix of information to the delta between disclosed and undisclosed projections. And I acknowledge that comparing projections using different metrics (EBITDA vs. revenue) over different time periods (one year vs. ten years) is an imperfect analysis. But here, I do not believe a reasonable stockholder would find the November LRP projections important in deciding whether to tender her shares, or that disclosing them would have significantly altered the total mix of information available to Tesaro stockholders. 104 Plaintiff also argues that the Recommendation Statement was materially misleading because it suggested that the Board considered two sets of projections (Case A and Case

40 Despite the relatively small gap between the November LRP and the Case A

projections, Plaintiff concludes that had Citi and Centerview used the November

LRP projections to analyze the transaction, “they could not have justified the

Acquisition price,” and thus, their omission is material.105 This argument falls flat.

While another set of inputs may have altered the fairness opinions’ valuation ranges,

“a complaint about the accuracy or methodology of a financial advisor’s report is

not a disclosure claim.”106 And though stockholders are entitled to a “fair summary”

of a financial advisor’s work, disclosures must “be sufficient for the stockholders to

B), but the “LRP Case Review” identified four sets of projections (Case A, Case B, the November LRP, and the August LRP). This argument fails for the same reason. Omitting mention of “the existence of more optimistic projections” that are themselves not substantially different from the projections discussed does not amount to a “materially misleading” disclosure and its inclusion would not have altered the total mix. See Simonetti, 2008 WL 5048692, at *9–10; In re BioClinica, Inc. S’holder Litig., 2013 WL 673736, at *6 (Del. Ch. Feb. 25, 2013) (discussing Simonetti). Similarly, Plaintiff alleges the Recommendation Statement was misleading in suggesting that Case A and Case B were an evolution or iteration of the LRP, arguing in a footnote that all three projections were prepared contemporaneously. Compl. ¶¶ 188, 191 (quoting the Recommendation Statement); D.I. 38 at 18 n.2. Plaintiff’s footnote falls short of proper briefing, such that this issue may be deemed waived. In re Tesla Motors, Inc. S’holder Litig., 2018 WL 1560293, at *20 (Del. Ch. Mar. 28, 2018). And Plaintiff has not demonstrated that the Recommendation Statement’s explanation that management created the LRP, as well as Case A and Case B, was in any way false or misleading. See Kirby Decl. Ex. P at 58. 105 Compl. ¶ 182. 106 Rouse, 2018 WL 1226015, at *23 n. 194 (quoting In re BioClinica, Inc. S’holder Litig., 2013 WL 5631233, at *10 (Del. Ch. Oct. 16, 2013)); Cty. of York Empls. Ret. Plan v. Merrill Lynch & Co., Inc., 2008 WL 4824053, at *11 (Del. Ch. Oct. 28, 2008); In re MONY Grp. Inc. S’holder Litig., 852 A.2d 9, 28 & n.52 (Del. Ch. 2004) (“Neither use of the purchase accounting method in this analysis, not mere disagreement with a financial advisor’s chosen methodology creates a disclosure claim.”).

41 usefully comprehend, not recreate, the analysis.”107 Delaware law does not require

disclosure of sufficient detail to “facilitate the recreation of a DCF analysis” or “to

enable a stockholder to make an independent determination of fair value.”108 The

inquiry is whether the November LRP projections themselves were material to

Tesaro stockholders. Though they may have been helpful to a stockholder seeking

to test Plaintiff’s theory by recreating the DCF analyses, their omission from the

Recommendation Statement was not material.

b. Citi’s Conflicts

Plaintiff contends the Recommendation Statement did not disclose the full

extent of Citi’s conflict of interest with GSK. In particular, Plaintiff argues that

Hite’s work with GSK in June 2018 and Hite’s simultaneous work on the

GSK/Pfizer JV are undisclosed conflicts of interest. For their part, Defendants point

to the disclosures in the Recommendation Statement, which indicate that: (1) Citi

and its affiliates have provided and currently provide services to GSK unrelated to

the Acquisition, (2) that Citi’s “investment banking services” for GSK include

“acting as a financial advisor in strategic transactions,” and “providing market

feedback and strategic advice,” for which Citi has been and will be paid; and (3)

107 Saba Software, 2017 WL 1201108, at *10 (quoting Merge Healthcare, 2017 WL 395981, at *10); Rouse, 2018 WL 1226015, at *23 n. 194 (Del. Ch. Mar. 9, 2018). 108 Rouse, 2018 WL 1226015, at *22; Dent, 2014 WL 2931180, at *14 (noting that “this argument has been rejected explicitly by our Supreme Court” in Skeen, 750 A.2d at 1174).

42 over the past two years, Citi has received approximately $24.1 million in fees from

GSK for its services.109 These disclosures are sufficient to inform Tesaro

stockholders of Citi’s conflict.

Both Citi’s fairness opinion, and the Recommendation Statement itself,

discussed Citi’s potential conflicts of interest. The Recommendation Statement

disclosed:

During the past two years, Citi has received approximately $24.1 million in fees for investment banking services provided to [GSK] and its affiliates. Investment banking services include acting as financial advisor in strategic transactions to [GSK], including in connection with the acquisition of the remaining stake held by Novartis AG in their Consumer Healthcare Joint Venture, placement agent for [GSK] on a sale of equity that it owned of a third party, joint bookrunner for an unsecured note offering of [GSK], underwriter, bookrunner, mandated lead arranger and facility agent under a committed facilities agreement of [GSK], corporate broker providing market feedback and strategic advice to [GSK], and as a financial advisor providing markets and securities services, treasury and trade solution services and corporate portfolio management services to [GSK].

In the ordinary course of its business, Citi and its affiliates may actively trade or hold the securities of [Tesaro] and [GSK] and affiliated entities for its own account or for the account of its customers and, accordingly, may at any time hold a long or short position in such securities. In addition, Citi and its affiliates (including Citigroup Inc. and its affiliates) may maintain relationships with [Tesaro], [GSK] and their respective affiliates.110

Citi’s fairness opinion elaborated:

109 Kirby Ex. P at 39, 69. 110 Id. at 39.

43 Citigroup Global Markets Inc. has acted as financial advisor to Tesaro in connection with the proposed Transaction and will receive a fee for such services, a significant portion of which is contingent upon the consummation of the Transaction. We also will receive a fee in connection with the delivery of this opinion. We and our affiliates in the past have provided, and currently provide, services to Tesaro and GSK unrelated to the proposed Transaction, for which services we and such affiliates have received and expect to receive compensation, including, without limitation, during the past two years, having acted or acting (i) as a lead bookrunner for follow-on offerings of Tesaro and as a financial advisor providing markets and securities services to Tesaro, and (ii) as financial advisor in strategic transactions to GSK, including in connection with the acquisition of the remaining stake held by Novartis in their Consumer Healthcare Joint Venture, placement agent for GSK on a sale of equity that it owned of a third party, joint bookrunner for an unsecured note offering of GSK, underwriter, bookrunner, mandated lead arranger and facility agent under a committed facilities agreement of GSK, corporate broker providing market feedback and strategic advice to GSK, and as a financial advisor providing markets and securities services, treasury and trade solution services and corporate portfolio management services to GSK. In the ordinary course of our business, we and our affiliates may actively trade or hold the securities of Tesaro and GSK for our own account or for the account of our customers and, accordingly, may at any time hold a long or short position in such securities. In addition, we and our affiliates (including Citigroup Inc. and its affiliates) may maintain relationships with Tesaro, GSK and their respective affiliates.111

The Recommendation Statement did not mention Citi’s June 2018 presentation of

public information on Tesaro to GSK, nor did it specifically identify the GSK/Pfizer

JV.

“Because of the central role played by investment banks in the evaluation,

exploration, selection, and implementation of strategic alternatives, this Court has

111 Id. at 69.

44 required full disclosure of investment banker compensation and potential

conflicts.”112 Disclosing conflicts is particularly important when the transaction in

question did not involve a public option, and so “shareholders may be forced to place

heavy weight upon the opinion of” a financial advisor.113 In that context, “[i]t is

imperative that stockholders be able to decide for themselves what weight to place

on a conflict faced by the financial advisor.”114

The financial advisor’s opinion of financial fairness for a proposed transaction is one of the most important process-based underpinnings of a board’s recommendation of a transaction to its stockholders and, in turn, for the stockholders’ decisions on the appropriateness of the transaction. Thus, it is imperative for the stockholders to be able to understand what factors might influence the financial advisor’s analytical efforts.115

When a financial advisor faces a conflict, this Court has generally required

disclosure of the relationship itself and the amount of fees the advisor received.116 It

112 In re Del Monte Foods Co. S’holders Litig., 25 A.3d 813, 832 (Del. Ch. 2011). 113 In re John Q. Hammons Hotels Inc. S’holder Litig., 2009 WL 3165613, at *16 (Del. Ch. Oct. 2, 2009) (internal quotation marks omitted) (quoting Braunschweiger v. Am. Home Shield Corp., 1991 WL 3920, at *6 (Del. Ch. Jan. 7, 1991)). 114 Id. 115 Simonetti, 2008 WL 5048692, at *8. 116 E.g., Saba Software, 2017 WL 1201108, at *11 (“What was material, and disclosed, was the prior working relationship and the amount of fees.”); see also Rouse, 2018 WL 1226015, at *24 n. 203 (compiling sources).

45 has rejected requests for more granular details about the “specific services rendered”

by the advisor,117 or overlapping deal team members.118

The Recommendation Statement sufficiently informs stockholders about

Citi’s potential conflict of interest with GSK. It discloses that Citi has represented

and still represents GSK on a variety of matters, and listing several of the services

Citi provides.119 In addition to disclosing the existence of the conflict and the general

nature of Citi’s work with GSK, the Recommendation Statement disclosed the

specific amount of fees GSK paid Citi over the last two years.120

Identifying Hite by name was unnecessary. In David P. Simonetti Rollover

IRA v. Margolis, this Court rejected a similar argument that overlapping deal team

members should be disclosed.121 Because the proxy statement disclosed the nature

of the conflict faced by the bank itself, the Simonetti Court held that “[n]o further

disclosures on this point would have altered the total mix of information available,

viz., that the same investment bank had represented parties with opposed interests in

117 Saba Software, 2017 WL 1201108, at *11. 118 Simonetti, 2008 WL 5048692, at *7. 119 Kirby Ex. P at 39, 69. 120 Id. 121 See 2008 WL 5048692, at *7.

46 the Merger in temporal proximity.”122 Here, too, the disclosures of Citi’s

relationship with GSK were sufficient without identifying Hite.

Information on Citi’s ongoing relationship with GSK in the context of the

GSK/Pfizer JV also exceeds what is necessary to disclose. Tesaro disclosed that Citi

was continuing to represent GSK in unrelated matters.123 As in In re Saba Software,

Inc. Stockholder Litigation, more information about the “specific services” Citi

rendered, including identifying the then-confidential GSK/Pfizer JV,124 would likely

not have substantially altered the total mix of information available to

stockholders.125

Plaintiff argues that the Recommendation Statement should have, but did not,

disclose that Citi included Tesaro in June 2018 pitches to GSK. Citi’s Conflict

Presentation, which is consistent with the Complaint, explains this meeting was not

a specific pitch to buy Tesaro, but rather one of several regular “strategic

discussions” in which Tesaro was among a broad swath of potentially available

oncology targets identified using “public marketing valuation materials.”126 The

122 Id. 123 Kirby Ex. P at 39, 69. 124 Kirby Ex. M at 4, 6. 125 2017 WL 1201108, at *11. 126 Compl. ¶ 158; Kirby Decl. Ex. M at 6 (stating that “[a]ny references to [Tesaro] were based solely on public information”).

47 Complaint does not allege this overview presentation suggested any particular

transaction or the terms of any such transaction. Citi’s presentation falls far short of

the material undisclosed communications in Chester County Employees’ Retirement.

Fund v. KCG Holdings., Inc.,127 In re PLX Technology Inc. Stockholders

Litigation,128 and In re John Q. Hammons Hotels Inc. Shareholder Litigation,129

which Plaintiff invokes. The communications in KCG and PLX were substantially

more involved, and shared crucial, non-public information.130 Hammons, which

involved the target’s financial advisor’s undisclosed pitch to secure other business

127 2019 WL 2564093. 128 2018 WL 5018535 (Del. Ch. Oct. 16, 2018), aff’d, 211 A.3d 137 (Del. 2019). 129 2009 WL 3165613, at *16 (Del. Ch. Oct. 2, 2009). 130 In KCG, the proxy suggested that the buyer had made a “vague or undeveloped” proposal to divest certain of the target’s assets upon completing a transaction. KCG, 2019 WL 2564093, at *11. The plaintiff alleged that the divestiture plan was far from undeveloped and, in fact, had been developed by the buyer and the target’s financial advisor in advance. See id. To help buyer develop that plan, thus facilitating the merger, the financial advisor provided specific, confidential information to the buyer in advance, a fact which the proxy omitted. See id. at *4, 11. The Court concluded that the omission of this information rendered the proxy materially misleading, since the proposal was not vague or undeveloped. See id. at *11–12. The undisclosed communication in PLX was similarly laden with insider information. 2018 WL 5018535, at *32–35. There, a representative from a potential bidder tipped off the target’s financial advisor of the price it planned to pay, and when it planned to make its bid. Id. at 33. The tip made it back to an activist investor, who was pressuring the target to sell. Id. Later, the activist investor and the bidder’s representative held substantial undisclosed price discussions over dinner. Id. 33– 34. Here, the allegations to not rise to the same level of severity. Disclosure of the details of Citi’s June 2018 presentation, which included only public information (unlike KCG), and did not discuss the details of a potential transaction (unlike PLX), would not have “substantially altered the total mix” of information available to Tesaro stockholders.

48 from the buyer, is also distinguishable.131 There, no conflict had been disclosed at

all, so disclosure of the pitch was necessary to inform the target’s stockholders of

the relationship in the first instance.132 The Recommendation Statement adequately

disclosed Citi’s work with GSK.

c. Mott’s and NEA’s Liquidity Conflicts

The Recommendation Statement disclosed that Mott is a general partner of

NEA; that NEA 13 and NEA 15 owned 9,681,039 and 739,516 shares of Tesaro

stock, respectively; and that the NEA funds had already agreed to tender its shares.133

Plaintiff argues that the Recommendation Statement materially omitted that NEA,

and by extension, Mott as an NEA partner, “had a unique interest in selling Tesaro

before year-end 2018[, which] would have been material to Tesaro’s stockholders

as it would have raised questions about, among other things, the rushed single bidder

process.”134 Defendants attack both the viability of Plaintiff’s liquidity conflict

theory in general, and whether that specific conflict needed to be disclosed.

131 2009 WL 3165613, at *16. 132 See id. 133 See Kirby Decl. Ex. P at 5–6, 15. 134 Compl. ¶ 203. While Plaintiff has alleged that other board members had ties to NEA, Plaintiff’s disclosure issue is specifically trained on Mott. See id. ¶¶ 69, 202–03, 230–31. Plaintiff does not assert any disclosure shortcomings in regard to Patel, an NEA venture partner.

49 Generally, stockholders are entitled to know whether their fiduciaries face

conflicts of interest.135 To plead that a fiduciary is conflicted, a plaintiff must “allege

facts that support a reasonable inference of a divergent interest, regardless of the

source, that rises to the level of a disabling conflict.”136 This Court has recognized

several potential sources of divergent interests, including more or different

consideration, or other uniquely valuable incidental benefits that may flow to a

fiduciary in a transaction.137

Plaintiff asserts NEA, and Mott by extension, sought and obtained the unique

benefit of liquidity for NEA. Specifically, Plaintiff asserts NEA sought a sale of

Tesaro by the end of 2018 to boost NEA 13 returns in support of fundraising and

135 E.g., van der Fluit v. Yates, 2017 WL 5953514, at *8 (Del. Ch. Nov. 30, 2017) (“Under Delaware law, stockholders are entitled to know that certain of their fiduciaries have a self- interest that is arguably in conflict with their own.” (alterations and internal quotation marks omitted) (quoting Eisenberg v. Chi. Milwaukee Corp., 537 A.2d 1051, 1061 (Del. Ch. 1987))); see also In re Lear Corp. S’holder Litig., 926 A.2d 94, 114 (Del. Ch. 2007) (“Put simply, a reasonable stockholder would want to know an important economic motivation of the negotiator singularly employed by a board to obtain the best price for the stockholders, when that motivation could rationally lead that negotiator to favor a deal at a less than optimal price, because the procession of a deal was more important to him, given his overall economic interest, than only doing a deal at the right price.”); RBC Cap. Mkts., LLC v. Jervis, 129 A.3d 816, 860 n.157 (Del. 2015) (quoting Lear, 926 A.2d at 114); In re Columbia Pipeline Grp., Inc., 2021 WL 772562, at *33–34 (Del. Ch. Mar. 1, 2021) (quoting Lear, 926 A.2d at 114). 136 Presidio, 251 A.3d at 256. 137 Flannery v. Genomic Health, Inc., 2021 WL 3615540, at *17 (Del. Ch. Aug. 16, 2021).

50 fees for NEA 17. Plaintiff’s theory is not new.138 In general, this Court has been

skeptical of liquidity-driven conflict theories.

Delaware courts have been reluctant to find that a liquidity-based conflict rises to the level of a disabling conflict of interest when a large blockholder receives pro rata consideration. To reach such a conclusion requires the court to make the extraordinary inference that rational economic actors have chosen to short-change themselves in favor of liquidity. Accordingly, in most cases, a fiduciary’s financial interest in a transaction as a stockholder (such as receiving liquidity value for her shares) does not establish a disabling conflict of interest when the transaction treats all stockholders equally.139

Given these concerns, it is unsurprising that “liquidity-driven theories of conflicts

can be difficult to plead.”140

Building on his decision rejecting a liquidity conflict theory in In re Synthes,

Inc. Shareholder Litigation,141 then-Chancellor Strine addressed a liquidity conflict

allegedly faced by a company’s private equity sponsor in In re Morton’s Restaurant

Group, Inc. Shareholders Litigation.142 Like this case, Morton’s presented the

theory that the company’s private equity sponsor, which was not a controlling

138 See Mindbody, 2020 WL 5870084, at *15 n. 117, *18 n. 156 (compiling sources). 139 Presidio, 251 A.3d at 256 (citations, alterations, and internal quotation marks omitted) (quoting Larkin, 2016 WL 4485447, at *16, and then quoting In re Synthes, Inc. S’holder Litig., 50 A.3d 1022, 1035 (Del. Ch. 2012)). 140 Mindbody, 2020 WL 5870084, at *18. 141 50 A.3d 1022. Last year, then-Vice Chancellor McCormick explained the “hyperbolic” “fire sale” language in Synthes “is best read in the context it was issued,” not to establish a general rule. Mindbody, 2020 WL 5870084, at *17 (citing Synthes, 50 A.3d at 1037). 142 74 A.3d 656 (Del. Ch. 2013).

51 stockholder but held two out of ten board seats, had life-cycle-driven reasons to

liquidate its position.143

The sponsor in Morton’s allegedly “pressured the board to sell Morton’s

quickly” so that it could “get some liquidity to reinvest in its new [fund], or so [it]

could cash out the investors in [its old fund] and those investors would have money

to reinvest in [the private equity sponsor’s] new [f]und.”144 Despite allegations that

the private equity sponsor’s typical life cycle involved periodically and

systematically liquidating its position to finance new investments and raise new

funds, the Court rejected the theory.145 It noted the plaintiff’s theory would require

finding a conflict “whenever [a private equity company] is in the process of starting

a new investment fund,” a “hardly unique” position that did not dislodge the

presumptions that large blockholders and board members are incentivized to

maximize share value in a change of control transaction.146

While the parties were briefing the Motions, this Court again rejected sponsor

life cycle cyclicality as a source of conflict in Firefighters’ Pension System of City

143 Id. at 661–62, 667–68. 144 Id. at 667. 145 Id. at 667–68. 146 Id. (citing Unitrin, Inc. v. Am. Gen. Corp., 651 A.2d 1361, 1380–81 (Del. 1995)); see also id. at 670–72 (explaining alignment between private equity firm incentives and other target stockholders).

52 of Kansas City, Missouri Trust v. Presidio, Inc.147 Presidio addressed the theory that

the target’s private equity sponsor and controlling stockholder, Apollo, “wanted to

sell because under its private equity business model, the time had come for Apollo

to harvest its investment in the Company.”148 Like Morton’s before it, Presidio

rejected the plaintiff’s theory that Apollo faced a debilitating conflict.149

It is true that investment fund managers cycle through a multi-year process of raising capital for a new fund, launching the fund, investing the fund’s capital, managing the investments, and then harvesting the investments. Investment managers may manage multiple funds at different stages, and they often raise or at least prepare to raise a new fund while in the harvesting stage for an old fund.

The desire to wrap up an existing fund or to provide potential investors with attractive realizations while raising a new fund can affect a fund manager’s approach to achieving liquidity for an investment. The cyclical process, however, is not so formulaic and structured that the cycle itself would support an inference of a liquidity-based conflict. Instead, this court has reasoned that because investment managers cyclically raise and liquidate funds on a somewhat predictabl[e] schedule, the pattern suggests that the monetization phase does not necessarily create a problematic interest.150

147 251 A.3d 212 (Del. Ch. 2021). 148 Presidio, 251 A.3d at 257. 149 Id. at 257 & n.10 (citing Mindbody, 2020 WL 5870084, at *34, then citing In re Crimson Expl. Inc. S’holder Litig., 2014 WL 5449419, at *19 (Del. Ch. Oct. 24, 2014), then citing Morton’s, 74 A.3d at 667, and then citing Chen v. Howard-Anderson, 87 A.3d 648, 671– 72 (Del. Ch. 2014). Like Mindbody, but unlike Morton’s, Presidio did not cabin a potential liquidity conflict to the extreme circumstances described in Synthes. 150 Id. at 257–58 (footnote omitted) (citing Larkin, 2016 WL 4485447, at *15–16).

53 Earlier this month, Vice Chancellor Slights summarized Presidio as standing for the

proposition that “the cyclicality of private equity funds, by itself, [does] not give rise

to a liquidity-based conflict.”151

Plaintiff here seeks the “extraordinary inference” that NEA, a Tesaro

stockholder that received the same Acquisition consideration as all other

stockholders, had an interest in “short-chang[ing] [itself] in favor of liquidity” due

to its investment life cycle and business model.152 Plaintiff’s inference rests on shaky

ground, as evidenced by Morton’s, Presidio, and others.153

In assessing Plaintiff’s conflict theory, it is important to remain oriented to the

task at hand: considering whether that conflict had to be disclosed to stockholders

for their votes to be fully informed under Corwin. Plaintiff argues NEA’s liquidity

interests are divergent from Tesaro stockholders’ interests in value, and because

151 Flannery, 2021 WL 3615540, at *18. 152 Presidio, 251 A.3d at 256 (internal quotation marks omitted) (quoting Larkin, 2016 WL 4485447, at *16). 153 See Presidio, 251 A.3d at 256–58; Morton’s, 74 A.3d at 667–69 (Del. Ch. 2013); see also Synthes, 50 A.3d 1022, 1035–36 (Del. Ch. 2012); Crimson Expl., 2014 WL 5449419, at *19; Chen, 87 A.3d at 671–72. Plaintiff seizes on one of the factual deficiencies in the Presidio conflict allegations, where the plaintiff alleged only the controller’s need for a “near-term” sale, rather than a need for a sale by a particular date or general time period. Presidio, 251 A.3d at 258. Plaintiff argues he has specifically established that NEA needed a sale by the end of 2018 to bolster its NEA 17 fundraising efforts. While Presidio noted that the timing deficiency there was important, it also identified several other places where the allegations fell short. See id. at 256–60. Even with Plaintiff’s added detail, I remain skeptical that Plaintiff’s liquidity conflict theory here is meaningfully different than the theory rejected in Presidio and its forebears.

54 NEA’s liquidity interests were not disclosed, the stockholders were not informed

and their vote did not cleanse Tesaro’s sale. It is important to remember that Plaintiff

has disclaimed any argument that NEA is a controller: it was not a fiduciary and did

not have its own power to pressure or force Tesaro’s sale.154 The Board was under

no obligation to disclose the business model of a minority stockholder, even if that

model conflicted with the pursuit of value. Whether NEA was conflicted is not

material on a standalone basis.

Rather, NEA’s interests are only relevant insofar as they inform whether Mott

was conflicted.

As in all matters of public disclosure, materiality is the touchstone of the board’s disclosure duty. This is true with respect to the disclosure of director conflicts. And not every fact tending remotely to suggest that a board member’s interest might differ in some respect from that of the stockholders amounts to a material omission. Plaintiffs must allege facts from which the Court may reasonably infer that there is a substantial likelihood that a reasonable shareholder would consider the omission important in deciding how to vote.155

Materiality is a case-specific endeavor.156

154 See Hr’g Tr. 67:5–9; D.I. 38 at 60–61. Plaintiff presents only conclusory allegations that Mott took action on NEA’s behalf. See Compl. ¶¶ 230–31. 155 In re OM Gp., Inc. S’holders Litig., 2016 WL 5929951, at *15 (Del. Ch. Oct. 12, 2016) (footnotes, alterations and internal quotation marks omitted) (quoting Rosenblatt, 493 A.2d at 944 (Del. 1985)). 156 See Highland Cap., Inc. v. Longview Fibre Co., 1990 WL 3973, at *5 (Del. Ch. Jan. 22, 1990).

55 The Recommendation Statement disclosed Mott was a dual fiduciary to both

NEA and Tesaro.157 The Recommendation Statement specifically states that Mott is

a general partner at NEA; it goes on to explain that NEA holds a substantial number

of shares and planned to tender them in the Acquisition.158 Stockholders were told

Mott’s dual fiduciary status, and his competing principal’s identity and directional

decision on the tender offer. The fact of Mott’s conflict was disclosed.

Plaintiff seeks more. Plaintiff asserts NEA’s liquidity interests, filtered

through Mott, were material to stockholders understanding and questioning “the

rushed single-bidder process” that led to the Acquisition.159 Even assuming NEA

has divergent liquidity interests, those specific interests do not add to the total mix

of stockholder information about Mott or the sale process, because neither Mott nor

NEA is alleged to have participated in the Acquisition process in any specific or

157 See Weinberger v. UOP, 457 A.2d 701, 710–11 (Del. 1983) (discussing the “dual fiduciary” problem). In evaluating whether a dual fiduciary faces a conflict, the Court looks to the two principals’ interests: “[i]f the interests of the beneficiaries to whom the dual fiduciary owes duties diverge, the fiduciary faces an inherent conflict of interest. But if the interests of the beneficiaries are aligned, then there is no conflict.” Chen, 87 A.3d at 670 (Del. Ch. 2014) (footnotes omitted) (citing Van de Walle v. Unimation, Inc., 1991 WL 29303, at *11 (Del. Ch. Mar. 7, 1991)); see PLX, 2018 WL 5018535, at *40 (quoting Chen, 87 A.3d at 670); Presidio, 251 A.3d at 284 (Del. Ch. 2021) (citing Chen, 87 A.3d at 670); see also In re Trados Inc. S’holder Litig. (Trados II), 73 A.3d 17, 47 (Del. Ch. 2013). 158 See Kirby Decl. Ex. P at 6. 159 Compl. ¶ 203. For purposes of this analysis, I accept Plaintiff’s description of Tesaro’s sale process.

56 remarkable way.160 The Complaint does not allege that Mott contributed to any

deficiency in the sales process, or that NEA was involved at all. 161 Rather, the

Complaint places blame squarely on Citi, Hite, and Tesaro management.162

Similarly, the Recommendation Statement does not indicate that Mott had any

substantial role in negotiating the Acquisition.163 In this case, absent any allegation

of bad acts, or even any act at all, further detail about the depths of Mott’s allegedly

bad intentions is immaterial.164

160 This is despite the benefit of documents from the Section 220 Action. While the Complaint repeatedly alleges that it would have been in NEA’s interests to “engineer” a near-term sale, e.g., Compl. ¶¶ 3, 81, 107, 141, 159, it stops conspicuously short of alleging that NEA (or Mott) did so. Indeed, there are no allegations that Mott participated in the process at all. See Hr’g Tr. 75:3–76:8. The closest the Complaint comes to pleading facts suggesting Mott’s or NEA’s involvement is the allegation that “[i]nferably, Mott knew that Tesaro management had provided Hite with valuation materials for delivery to GSK.” Compl. ¶ 159. Putting aside the problems of pleading an “inference,” Mott’s knowledge of Citi’s June 2018 presentation of public information does not suggest any wrongdoing. Nor do Plaintiff’s allegations that NEA and GSK crossed paths in other investments, and that one of Mott’s former colleagues at NEA had served as a consultant to GSK. See id. Plaintiff’s bare allegation that Mott “used his personal and professional connections to engineer the Acquisition” is unsupported and conclusory. See id. ¶ 230. 161 See id. ¶ 203. E.g., id. ¶¶ 5, 157–76; see also id. at 58 (“Citi’s Hite Arranges the Acquisition and 162

Deceives the Board”). 163 See Kirby Decl. Ex. P at 16–27. The only mentions of Mott during the negotiation process were two meetings he attended with representatives from “Party C” and “Party D” regarding potential business combinations. See id. at 20, 22. Plaintiff does not assert the Recommendation Statement was incomplete on this topic. 164 See Morrison, 191 A.3d 268 at 283–84 (holding that omitted “troubling facts regarding director behavior” during the sale process were material because their inclusion “would have helped the stockholder reach a materially more accurate assessment of the probative value of the sale process”); OM Gp., 2016 WL 5929951, at *16 (“Plaintiffs do not allege that . . . Demetriou controlled or had undue influence over any other members of the OM

57 d. Valuation Information For The BMS Collaboration And RP Royalty Transaction

Finally, Plaintiff complains that the Recommendation Statement omitted Citi

and Centerview’s valuation analyses for the BMS Collaboration and the RP Royalty

transactions. This contention also fails to demonstrate Tesaro stockholders were not

fully informed when they tendered their shares. The Recommendation Statement

disclosed that the Board explored several strategic transactions with anonymized

parties that would not have required a sale.165 It described in some detail the

negotiations surrounding those transactions and some proposed terms.166

Board. Plaintiffs’ conclusory allegation that ‘Demetriou was influenced to support the Transaction’ due to his ‘pre-existing relationship with OM’s counterparty Apollo’ does not make it reasonably conceivable that this information should have been inserted in the Proxy or, if it was included, that it would have changed the total mix of information available to investors or would be important to a reasonable investor in deciding how to vote her shares. Thus, . . . without even the slightest indication much less allegation that Demetriou could exercise undue influence over the other indisputably independent members of the OM Board, I cannot accept Plaintiffs’ contention that the omission of facts relating to the Demetriou ‘conflict’ was material.”); see also Morton’s, 74 A.3d at 667 (rejecting liquidity conflict theory where “plaintiffs have essentially admitted that [the private equity sponsor] did not cause [the company] to be sold at less than fair market value in a rushed fire sale, but that it simply supported the sale of the company after a full and unhurried market check.”); Columbia Pipeline, 2021 WL 772562, at *34 & n.11 (noting that “precedents support the materiality of information that sheds light on the financial incentives and motivations of key members of management who are involved in negotiating the deal” and compiling sources). 165 See Kirby Decl. Ex. P at 17–25. 166 See id.

58 As discussed above, stockholders considering a proposed merger “are entitled

to a fair summary of the substantive work performed by the investment bankers upon

whose advice the recommendations of their board as to how to vote on a merger or

tender offer rely.”167 But “Delaware law does not require disclosure of a play-by-

play of negotiations leading to a transaction or of potential offers that a board has

determined were not worth pursuing.”168 And a disclosure claim will not be

supported where it “boil[s] down to an argument that plaintiff disagreed with a

Special Committee’s decision not to pursue another acquisition proposal and that

other stockholders should have been informed about the offer in case they, too,

disagreed with the Special Committee.”169 As then-Chancellor Chandler observed

in In re 3Com Shareholders Litigation, “Delaware law does not require management

to discuss the panoply of possible alternatives to the course of action it is

proposing.”170 Nor does it “mandate the disclosure of every conceivable valuation

167 Saba Software, 2017 WL 1201108, at *10 (quoting In re Pure Res., Inc., S’holders Litig., 808 A.2d 421, 449 (Del. Ch. 2002)). 168 City of Miami Gen. Empls.’ v. Comstock, 2016 WL 4464156, at *15 (Del. Ch. Aug. 24, 2016); see also Simonetti, 2008 WL 5048692, at *12 (“In the usual case, where a board has not received a firm offer or has declined to continue negotiations with a potential acquirer because it has not received an offer worth pursuing, disclosure is not required.”). 169 OM Gp., 2016 WL 5929951, at *14 (internal quotation marks omitted) (quoting Comstock, 2016 WL 4464156, at *15). 170 In re 3Com S’holders Litig., 2009 WL 5173804, at *6 (Del. Ch. Dec. 18, 2009) (alterations and internal quotation marks omitted) (quoting Seibert v. Harper & Row, Publ’rs, Inc., 1984 WL 21874, at *5 (Del. Ch. Dec. 5, 1984).

59 datum, method, or alternative.”171 This “settled guidance” is justified because

“stockholders have a veto power over fundamental corporate changes (such as a

merger) but entrust management with evaluating the alternatives and deciding which

fundamental changes to propose.”172

Plaintiff’s “tell me more” claims for the specific valuation ranges for the BMS

Collaboration and RP Royalty transactions do not present any reason to deviate from

this general rule. As in 3Com, Tesaro management did not need “to discuss the

panoply of possible alternatives to the course of action it is proposing.” 173 Indeed,

the Recommendation Statement here went further than the disclosure in 3Com,

disclosing the existence of several alternatives, as well as general information about

their terms and how they were negotiated.174 In deciding whether to “veto” the

171 In re Novell, Inc. S’holder Litig., 2013 WL 322560, at *13 (Del. Ch. Jan. 3, 2013). 172 3Com, 2009 WL 5173804, at *6; Saba Software, 2017 WL 1201108, at *13 (describing the general rule from 3Com as “settled guidance”). 173 See 3Com, 2009 WL 5173804, at *6 (quoting Seibert, 1984 WL 21874, at *5 (internal quotation marks omitted)). 174 See, e.g., Kirby Decl. Ex. P at 17–25 (discussing, among other things, potential Zejula co-development/co-promote transactions with several anonymized parties). While the Complaint does not match these anonymous parties with the BMS Collaboration or the RP Royalty transactions, it appears the Recommendation Statement disclosed these transactions. Party A’s proposed “global collaboration for the development and commercialization of [Zejula],” providing for “total potential payments of $1.79 billion split between upfront payments and potential contingent milestone payments,” in exchange for a share of “certain commercialization profits and losses of [Zejula], and . . . certain ZEJULA development expenses” appears to be the BMS Collaboration. Id. at 22. According to the Recommendation Statement, Party A’s proposal, like BMS’s, ultimately proposed payments up to $2.34 billion. Id. at 23; Compl. ¶ 145. Party C’s proposed “synthetic royalty transaction,” which would provide “$300 million of financing in

60 Acquisition, Tesaro stockholders did not need information about “every conceivable

valuation datum, method, or alternative.”175

Plaintiff relies on Saba Software for the proposition that “a reasonable

stockholder would have needed to understand what alternatives to the Merger

existed.”176 The exception carved out in that unique case is not applicable here.

After noting that 3Com’s general rule “holds true in a typical case,” the Saba

Software Court acknowledged that “this is hardly a typical case given the

deregistration of Saba’s shares by the SEC just prior to the time the stockholder vote

on the Merger was to occur.”177 Because of the “fundamental change to the nature

and value of the stockholder’s equity stake” caused by the deregistration, and the

impact that process had on “the environment in which the Board conducted the sales

process and in which stockholders were asked to exercise their franchise,” the Saba

Software Court cautioned that “[t]he Board needed to take extra care to account for

this dynamic in its disclosures to stockholders.”178 Based on these extenuating

exchange for royalties and milestone payments on the Company’s immuno-oncology assets, as well as an equity investment in the Company at a premium to the then trading price of the Company’s common stock” appears to be the RP Royalty deal. See Kirby Decl. Ex. P at 20–21. In addition to the quoted excerpts, the Recommendation Statement discusses some of the surrounding negotiations of these transactions through November 2018. 175 See Novell, 2013 WL 322560, at *13. 176 D.I. 38 at 77 (quoting 2017 WL 1201108, at *13). 177 Saba Software, 2017 WL 1201108, at *13. 178 Id.

61 circumstances, the Court held: “[i]n considering whether or not Saba was viable as

a going-concern without the Merger, a reasonable stockholder would have needed

to understand what alternatives to the Merger existed.”179

Those extraordinary circumstances are not present here. While Tesaro, like

many companies, needed additional cash to fuel its ambitious long-term plans, there

is no allegation that the company’s viability as a going concern was ever in question.

In this much more typical case, further disclosure about potential strategic

alternatives was not required. Armed with sufficient information about the proposed

Acquisition, and aware that the Board had considered and rejected other alternatives,

Tesaro stockholders were more than adequately positioned to consider whether to

veto the Acquisition.

2. Because Counts I And II Do Not Plead Waste, They Must Be Dismissed.

For the foregoing reasons, I am satisfied that Plaintiff has failed to plead that

the stockholders’ decision to tender their shares was not fully informed. Plaintiff

does not argue that decision was coerced or that a conflicted controlling stockholder

put the Acquisition beyond Corwin’s reach.

179 Id.

62 The legal effect of a fully-informed stockholder vote of a transaction with a non-controlling stockholder is that the business judgment rule applies and insulates the transaction from all attacks other than on the grounds of waste, even if a majority of the board approving the transaction was not disinterested or independent. As our Supreme Court explained, the long-standing policy of Delaware law has been to avoid the uncertainties and cost of judicial second-guessing when the disinterested stockholders have had the free and informed chance to decide on the economic merits of a transaction for themselves.180

Given Corwin’s application here, “the only claim Plaintiff[] could state that would

overcome application of the business judgment rule is a claim for waste.”181 Plaintiff

has not attempted to plead that claim. Thus, the Individual Defendants’ Motion is

granted with respect to the breach of fiduciary duty claims in Counts I and II.

B. Counts III and IV: Aiding and Abetting

Count III alleges NEA aided and abetted the breaches of fiduciary duty alleged

against the Individual Defendants. Count IV similarly alleges Citi aided and abetted

those breaches.

To plead a claim for aiding and abetting breach of fiduciary duty, a plaintiff must allege (i) the existence of a fiduciary relationship, (ii) a breach of the fiduciary’s duty, (iii) knowing participation in that breach by the defendants, and (iv) damages proximately caused by the breach. An adequate pleading of knowing participation requires a pleading of scienter.182

180 GGP, 2021 WL 2102326, at *34 (alterations and internal quotation marks omitted) (quoting KKR, 101 A.3d at 1001, and then quoting Corwin, 125 A.3d at 313). 181 Rouse, 2018 WL 1226015, at *25 (citing Volcano, 143 A.3d at 741). 182 RCS Cred. Tr. v. Schorsch, 2018 WL 1640169, at *5 (Del. Ch. Apr. 5, 2018) (internal quotation marks omitted) (quoting RBC Cap. Mkts., 129 A.3d at 861, and then quoting

63 “An aiding and abetting claim may be summarily dismissed based upon the failure

of the breach of fiduciary duty claims against the director defendants.”183 Lacking a

well-pled predicate breach of fiduciary duty, the Complaint does not state a claim

for aiding and abetting. The NEA Motion is granted with respect to Count III and

the Citi Motion is granted with respect to Count IV.

III. CONCLUSION

For the foregoing reasons, Defendants’ Motions are GRANTED.

Cumming v. Edens, 2018 WL 992877, at *26 (Del. Ch. Feb. 20, 2018)); see also Malpiede v. Townson, 780 A.2d 1075, 1096 (Del. 2001). 183 KKR, 101 A.3d at 1003 (internal quotation marks omitted) (quoting Meyer v. Alco Health Servs. Corp., 1991 WL 5000, at *2 (Del. Ch. Jan. 17, 1991)); see also Volcano, 143 A.3d at 750.